Abstract: Effective treatments of pain for extended periods of time are provided. Through the administration of an effective amount of clonidine at or near a target site, one can relieve pain caused by diverse sources, including but not limited to spinal disc herniation (i.e. sciatica), spondilothesis, stenosis, discogenic back pain and joint pain, as well as pain that is incidental to surgery. When appropriate formulations are provided within biodegradable polymers, this relief can be continued for at least three days. In some embodiments, the relief can be for at least twenty-five days, at least fifty days, at least one hundred days, at least one hundred and thirty-five days or at least one hundred and eighty days.
Type:
Grant
Filed:
January 29, 2015
Date of Patent:
September 19, 2017
Assignee:
Warsaw Orthopedic, Inc.
Inventors:
John Myers Zanella, Christopher M. Hobot, Danielle L. Biggs, Katara Shaw, Phillip Edward McDonald, Vanja Margareta King, William F. McKay, Kathy L. Remsen
Abstract: A liquid composition comprises an organic diluent and at least one cellulose ether having anhydroglucose units joined by 1-4 linkages and having methyl groups, hydroxyalkyl groups, and optionally alkyl groups being different from methyl as substituents such that hydroxyl groups of anhydroglucose units are substituted with methyl groups such that s23/s26 is 0.29 or less, wherein s23 is the molar fraction of anhydroglucose units wherein only the two hydroxyl groups in the 2- and 3-positions of the anhydroglucose unit are substituted with a methyl group and wherein s26 is the molar fraction of anhydroglucose units wherein only the two hydroxyl groups in the 2- and 6-positions of the anhydroglucose unit are substituted with a methyl group. The liquid composition can be used for preparing a solid dispersion of an active ingredient in a cellulose ether.
Type:
Grant
Filed:
April 8, 2013
Date of Patent:
September 12, 2017
Inventors:
Roland Adden, Robert L. Sammler, Meinolf Brackhagen, Nicholas S. Grasman, Oliver Petermann, Steven J. Guillaudeu
Abstract: Methods of selecting a chemotherapy regimen for treatment of cancer in a patient are disclosed. A patient genetic sample from a bilary cancer such as cholangiocarcinoma is analyzed for a mutation in ERRFI1 and a chemotherapeutic agent is selected as a result of the analysis. If a mutation in ERRFI1 is present, treatment with an inhibitor of Epidermal Growth Factor Receptor (EGFR) is shown to have inhibitory effects on tumor growth. In this manner, the chemotherapy regimen is targeted to a given mutation in a patient's cancer.
Type:
Grant
Filed:
March 17, 2014
Date of Patent:
September 5, 2017
Assignees:
The Translational Genomics Research Institute, MAYO Foundation for Medical Education and Research
Inventors:
Mitesh Jivraj Borad, David Craig, John Carpten
Abstract: The present invention is directed to immune adjuvants containing IAP inhibitors, including Smac mimetics. The invention further provides pharmaceutical compositions and vaccines containing an IAP inhibitor and an antigen. Methods of enhancing an immune response by administration of an IAP inhibitor, methods of treating or preventing cancer, methods of treating or preventing infections, methods of treating autoimmune disorders, and methods of potentiating cytokine or antibody production are also provided.
Type:
Grant
Filed:
May 14, 2009
Date of Patent:
September 5, 2017
Assignees:
Dana-Farber Cancer Institute, Inc., Novartis AG
Inventors:
Leigh Zawel, Christopher S. Straub, Brant G. Firestone, Glenn Dranoff, Michael Dougan
Abstract: Positive allosteric modulators of melanocortin receptors, especially allosteric potentiators of the receptors MC3R and MC4R are described herein. Also provided are pharmaceutical compositions containing the positive allosteric modulators and methods of treating obesity or an obesity-related disorder such as type 2 diabetes, comprising administering an effective amount of the positive allosteric modulator.
Type:
Grant
Filed:
March 6, 2013
Date of Patent:
August 29, 2017
Assignee:
Vanderbilt University
Inventors:
Roger D. Cone, Julien A. Sebag, Jacques Pantel, Savannah Y. Williams, David C. Weaver, Gary A. Sulikowski, Craig W. Lindsley, Padma S. Portonova, Chao Zhang
Abstract: Compositions, methods, and kits useful for treating pulmonary conditions are provided herein. Such compositions can contain synergizing amounts of a non-specific phosphodiesterase inhibitor, such as a methylxanthine, in combination with leucine and/or a leucine metabolite, and resveratrol.
Type:
Grant
Filed:
July 23, 2014
Date of Patent:
August 22, 2017
Assignee:
NuSirt Sciences, Inc.
Inventors:
Michael Zemel, Brooke Baggett, Antje Bruckbauer
Abstract: Disclosed herein are compositions and methods for treating schizophrenia and symptoms of schizophrenia, including negative symptoms of schizophrenia.
Type:
Grant
Filed:
July 20, 2011
Date of Patent:
August 15, 2017
Assignee:
Minerva Neurosciences, Inc.
Inventors:
Remy Henri Luthringer, Lorenzo Pellegrini, Argeris N. Karabelas
Abstract: The present invention discloses an anilino-substituted podophyllin derivative having antitumor activity, method for preparation thereof, and use thereof. By means of anilino reactions, the present invention introduces 4-chloro-3-methylaniline, 3-fluoro-4-methoxyaniline, 4,4?-diaminodiphenylmethane, o-anisidine, 4-chloro-2-aminoanisole, anthranilonitrile, 2,6-dichloro-4-aminophenol, N,N-dimethylamino meta-aniline, 2-ethyl-5-nitroaniline, 2 2?-diaminodiphenylsulfide, or 2-aminobenzotrifluoride into position 4 of the active C-ring of podophyllotoxin or 4?-demethylepipodophyllotoxin to obtain the aniline-substituted podophyllotoxin derivative shown in formula (V); by means of multi-pathway and multi-target effects on tumor cells, said derivative has significantly increased antitumor activity, and can be prepared as an antineoplastic drug and applied in clinical antitumor therapy.
Type:
Grant
Filed:
September 5, 2014
Date of Patent:
July 25, 2017
Assignee:
HUBEI UNIVERSITY OF TECHNOLOGY
Inventors:
Yajie Tang, Yong Yang, Wei Zhao, Hongmei Li
Abstract: The present invention relates generally to the field of lipids and in particular aims at improving lipid absorption, for example under conditions of lipid maldigestion or malabsorption. One embodiment of the present invention relates to a composition comprising a sn-2 monoacylglycerol derivative, wherein the sn-1 and sn-3 positions are blocked by protective groups. The acyl group may be a fatty acid, for example one with anti-inflammatory properties.
Type:
Grant
Filed:
November 10, 2016
Date of Patent:
June 27, 2017
Assignees:
Nestec S.A., Beth Israel Deaconess Medical Center, Inc.
Inventors:
Bruce Bistrian, Frederic Destaillats, Cristina Cruz-Hernandez, Fabiola Dionisi, Isabelle Masserey-Elmelegy, Manuel Oliveira, Julie Celine Moulin
Abstract: Disclosed are compounds of Formula (I): or a salt thereof, wherein: X is CR4 or N; R1, R2, R3, R4, and A are defined herein. Also disclosed are methods of using such compounds as inhibitors of Bruton's tyrosine kinase (Btk), and pharmaceutical compositions comprising such compounds. These compounds are useful in treating, preventing, or slowing the progression of diseases or disorders in a variety of therapeutic areas, such as autoimmune diseases and vascular disease.
Type:
Grant
Filed:
October 23, 2015
Date of Patent:
June 27, 2017
Assignee:
Bristol-Myers Squibb Company
Inventors:
Qingjie Liu, Scott Hunter Watterson, Saleem Ahmad
Abstract: A method for the prevention of filariasis includes administering to a subject a therapeutically effective amount of a compound of the general formula (1) or at least one of racemates, enantiomers, diastereomers, solvates, hydrates, pharmaceutically acceptable salts, and esters of general formula (1), wherein, R is selected from the group comprising n-propyl, n-butyl, and at least one of structural elements (2a), (2b), (3a), (3b), (4), (5), (6a), (6b), (7a), and (7b):
Inventors:
Kenneth Michael Pfarr, Achim Hoerauf, Gabriele Maria Koenig, Sabine Specht, Andrea Schiefer, Till Friedrich Schaeberle, Alexander Schmitz, Stefan Kehraus
Abstract: A ceramide production enhancer and a moisturizer containing, as an active ingredient, an extract of at least one plant selected from the group consisting of Chenopodium hybridum, Melia toosendan, Indigofera tinctoria, Cirsium japonicum, Catalpa ovata, and Tagetes erecta, or a compound represented by the following Formula (1): wherein, R represents an acyl group having 1 to 5 carbon atom(s).
Abstract: Methods and compositions are provided for treating neuropsychiatric disorders such as schizophrenia, depression, attention deficit disorder, mild cognitive impairment, dementia, and bipolar disorder. The methods entail administering to a patient diagnosed as having a neuropsychiatric disorder (e.g., schizophrenia, depression, attention deficit disorder, mild cognitive impairment, dementia bipolar disorder, etc.) or as at risk for a neuropsychiatric disorder a benzoic acid, benzoic acid salt, and/or benzoic acid derivative, and/or a sorbic acid, sorbic acid salt, and/or sorbic acid derivative, in combination with a neuropharmacological agent (e.g., an antipsychotic, an antidepressant, medications for attention deficit and hyperactivity disorder, cognitive impairment, or dementia, etc.) where the benzoic acid, benzoic acid salt, or benzoic acid derivative, and/or a sorbic acid, sorbic acid salt, and/or sorbic acid derivative, is in an amount sufficient to increase the efficacy of the neuropharmacological agent.
Type:
Grant
Filed:
November 24, 2014
Date of Patent:
June 13, 2017
Assignee:
Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center
Abstract: Beta-hydroxybutyrate mineral salts in combination with medium chain fatty acids or an ester thereof such as medium chain triglycerides were used to induce ketosis, achieving blood ketone levels of (2-7 mmol/L), with or without dietary restriction. The combination results in substantial improvements in metabolic biomarkers related to insulin resistance, diabetes, weight loss, and physical performance in a short period of time. Further, use of these supplements to achieve ketosis yields a significant elevation of blood ketones and reduction of blood glucose levels. Use of these substances does not adversely affect lipid profiles. By initiating rapid ketosis and accelerating the rate of ketoadaptation, this invention is useful for the avoidance of glucose withdrawal symptoms commonly experienced by individuals initiating a ketogenic diet, and minimizes the loss of lean body mass during dietary restriction.
Type:
Grant
Filed:
September 21, 2015
Date of Patent:
June 13, 2017
Assignee:
University of South Florida
Inventors:
Dominic Paul D'Agostino, Patrick Arnold, Shannon Kesl
Abstract: Materials and methods for stimulating or inhibiting germination of Paenibacillus larvae spores, including methods for inhibiting P. larvae germination to reduce foulbrood in honey bees.
Type:
Grant
Filed:
December 19, 2014
Date of Patent:
June 6, 2017
Assignee:
The Board of Regents of the Nevada System of Higher Education on Behalf of the University of Nevada, Las Vegas
Abstract: Methods and compositions are provided for treating neuropsychiatric disorders such as schizophrenia, depression, attention deficit disorder, mild cognitive impairment, dementia, and bipolar disorder. The methods entail administering to a patient diagnosed as having a neuropsychiatric disorder (e.g., schizophrenia, depression, attention deficit disorder, mild cognitive impairment, dementia bipolar disorder, etc.) or as at risk for a neuropsychiatric disorder a benzoic acid, benzoic acid salt, and/or benzoic acid derivative, and/or a sorbic acid, sorbic acid salt, and/or sorbic acid derivative, in combination with a neuropharmacological agent (e.g., an antipsychotic, an antidepressant, medications for attention deficit and hyperactivity disorder, cognitive impairment, or dementia, etc.) where the benzoic acid, benzoic acid salt, or benzoic acid derivative, and/or a sorbic acid, sorbic acid salt, and/or sorbic acid derivative, is in an amount sufficient to increase the efficacy of the neuropharmacological agent.
Type:
Grant
Filed:
January 19, 2010
Date of Patent:
May 16, 2017
Assignee:
Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center
Abstract: The invention relates to 2-oxo-1-pyrrolidinyl triazole derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals for enhancing the cognitive function or to counteract cognitive decline.
Abstract: The present application discloses compositions and methods useful for treating and preventing inflammation associated with inflammatory diseases and disorders.
Type:
Grant
Filed:
August 4, 2011
Date of Patent:
April 11, 2017
Assignee:
University of Virginia Patent Foundation
Abstract: Effective treatments of pain for extended periods of time are provided. Through the administration of an effective amount of clonidine in a drug depot at or near a target site, one can relieve pain caused by diverse sources, including but not limited to spinal disc herniation (i.e. sciatica), spondilothesis, stenosis, discogenic back pain and joint pain. When appropriate drug depot formulations are provided within biodegradable polymers, this pain relief can be continued for at least fourteen days.
Type:
Grant
Filed:
March 15, 2013
Date of Patent:
April 4, 2017
Assignee:
Warsaw Orthopedic, Inc.
Inventors:
Danielle L. Clay, Josee Roy, William F. McKay
Abstract: Polymeric compounds having spatially controlled bioconjugation sites are described. Functionalization is achieved by selective ?-terminal chain extension of polymer chains by radical polymerization, such as reversible addition-fragmentation chain transfer (RAFT) polymerization.
Type:
Grant
Filed:
December 8, 2009
Date of Patent:
March 14, 2017
Assignees:
University of Washington, PhaseRx, Inc.
Inventors:
Patrick S. Stayton, Allan S. Hoffman, Anthony J. Convertine, Scott M. Henry, Robert W. Overell, Paul H. Johnson